Defence Therapeutics Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Defence Therapeutics Inc. (CSE: DTC; OTCQB: DTCFF; FSE: DTC), a pre-clinical Canadian biotechnology company headquartered in Montreal, Quebec, develops the proprietary Accum platform to enhance intracellular drug delivery for biologics targeting cancer and infectious diseases. Founded in 2017 and formerly known as Accum Therapeutics Inc., the company focuses on oncology solutions including Accum-enhanced antibody-drug conjugates (ADCs) that boost potency up to 60-fold while reducing toxicity and dosing requirements; radio-immuno conjugates (rADCs) combining ADC precision with radioactive payloads such as Actinium-225 for solid tumors; the AccuTOX program, dimers of Accum with independent anti-cancer activity cleared for Phase I trials in melanoma by Health Canada and eligible for FDA studies; ARM-X mesenchymal stem cell-based cancer vaccines; Accuvac dendritic cell vaccines; protein-based formulations against COVID-19 and infectious diseases; and mRNA vaccination programs. Defence Therapeutics operates primarily in Canada with a global IP portfolio of eight granted US patents and pursues partnerships for ADC and radiopharma licensing worldwide. Recent developments include a fully subscribed CAD 2 million debenture financing in September 2025; formation of a Scientific Advisory Board in December 2025 to advance Accum-enhanced ADCs; an ongoing collaboration with Canadian Nuclear Laboratories on Actinium-225 radiotherapeutics; and a 50:50 joint venture with Orano to develop rADCs; alongside strategic outreach to ADC developers following presentations at the World ADC Conference and CPHI in 2025.
Company News
Defence Therapeutics Expands Radiopharmaceutical Development Strategy with Alpha and Beta-Emitter Programs
Defence Therapeutics Strengthens Radiopharmaceutical Leadership with Appointment of Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical Programs
Defence Therapeutics Appoints Dr. Amie Phinney as President and Chief Executive Officer
Defence Therapeutics Opens New Office in Hamilton to Expand Its Accum Radiopharmaceutical Platform
Defence Therapeutics to Participate in Bio International Convention 2026 Next Week for Strategic Partnership Discussions
Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of Directors
Defence Therapeutics Appoints Antibody Drug Conjugates Pioneer Dr. John Lambert to Its Board of Directors
Defence Therapeutics Strengthens Its Scientific Advisory Board with the Appointment of Dr. Sarkis Meterissian
Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities
Defence Therapeutics Announces Grant of Restricted Stock Units
Defence Therapeutics Announces Warrant Terms Amendment
Defence Therapeutics Announces Closing of Private Placement of Units for Gross Proceeds of $9,595,000
Defence Therapeutics to Showcase Accum Platform at Key International Industry Events in March
Defence Therapeutics Announces Private Placement of Units for Proceeds of up to $11 Million
Defence Therapeutics Aligns Accum ADC Strategy Through Multidisciplinary Scientific Advisory Board
Defence Therapeutics Expands Collaboration with Canadian Nuclear Laboratories to Accelerate Its Proprietary Radiopharmaceutical Pipeline
Defence Therapeutics (OTCMKTS:DTCFF) Stock Price Down 4.9% – Here’s Why
Defence Therapeutics Sharpens Strategic Focus on Precision Drug Delivery to Unlock the Full Potential of Cancer Biologics
Defence Therapeutics (OTCMKTS:DTCFF) Shares Down 5.9% – Here’s What Happened
Defence Therapeutics to Present at the Life Sciences Virtual Investor Forum December 11th